Sunho Biologics Past Earnings Performance
Past criteria checks 0/6
Sunho Biologics's earnings have been declining at an average annual rate of -34.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 5.4% per year.
Key information
-34.4%
Earnings growth rate
-23.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 5.4% |
| Return on equity | -19.6% |
| Net Margin | -927.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sunho Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 12 | -107 | 23 | 56 |
| 31 Mar 24 | 15 | -120 | 32 | 50 |
| 31 Dec 23 | 18 | -133 | 41 | 43 |
| 30 Sep 23 | 16 | -94 | 39 | 49 |
| 31 Dec 22 | 2 | -52 | 6 | 53 |
| 31 Dec 21 | 3 | -71 | 6 | 64 |
Quality Earnings: 2898 is currently unprofitable.
Growing Profit Margin: 2898 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2898's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2898's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2898 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 2898 has a negative Return on Equity (-19.58%), as it is currently unprofitable.